Last reviewed · How we verify
NCT04056988
tSCI Contrast Enhanced Ultrasound Study
Phase 4 trial testing Perflutren Lipid Microsphere in Acute Spinal Cord Injury in 9 participants. Completed in 20 November 2023.
20 November 2023
Quick facts
| Lead sponsor | University of Washington |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 9 |
| Start date | 31 July 2018 |
| Primary completion | 20 November 2023 |
| Estimated completion | 20 November 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Perflutren Lipid Microsphere — full drug profile →
Conditions studied
- Acute Spinal Cord Injury — all drugs for Acute Spinal Cord Injury →
Sponsor
University of Washington
Who can join
18 and older, any sex, with Acute Spinal Cord Injury. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patients with traumatic spinal cord injury (tSCI) often suffer from spinal cord swelling inside the thecal sac, which contains the spinal cord and surrounding fluid, leading to increased pressure on the spinal cord tissue and decreased spinal cord blood flow at the site of injury. The combination of increased pressure and decreased blood flow causes vascular hypo-perfusion of the spinal cord and exacerbates the severity of the injury. This is also referred to as secondary injury. Thus, knowledge of spinal cord hypo-perfusion would allow the treating physician to optimize the hemodynamic condition of patients with acute spinal cord injury and potentially improve functional outcomes. The investigators plan to use contrast-enhanced ultrasound (CEUS) to determine the decrease of blood flow in the spinal cord at the site of injury, during the routine surgery that these patients require to decompress and stabilize their injured spine. This may help the investigators to determine the efficacy of certain treatments in improving blood flow and patients suffering from tSCI.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Spinal cord injury: molecular mechanisms and therapeutic interventions.
Hu X, Xu W, Ren Y, Wang Z, et al · · 2023 · cited 400× · PMID 37357239 · DOI 10.1038/s41392-023-01477-6 -
Ultrasound in Traumatic Spinal Cord Injury: A Wide-Open Field.
Hwang BY, Mampre D, Ahmed AK, Suk I, et al · · 2021 · cited 23× · PMID 34098572 · DOI 10.1093/neuros/nyab177 -
Contrast enhanced ultrasound for traumatic spinal cord injury: an overview of current and future applications.
Saway BF, Courtney J, Barley J, Frankel B, et al · · 2024 · cited 3× · PMID 38664470 · DOI 10.1038/s41394-024-00644-3
Verify or expand the search:
- PubMed search for NCT04056988
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Spinal Cord Injury
Currently open trials in the same condition.
- NCT06452264 — Early Intervention for Information Processing Speed Deficits in Acute SCI: A Pilot Study · NA · recruiting
- NCT06238492 — A Pilot RCT to Improve Cognitive Processing Speed in Acute SCI · NA · recruiting
- NCT06654804 — Contrast-enhanced Ultrasound in the Treatment of Acute Spinal Cord Injury · Phase 4 · recruiting
- NCT05745298 — The Use of Functional Electrical Stimulation in Conjunction With Respiratory Muscle Training to Improve Unaided Cough in · NA · recruiting
- NCT05244408 — "SCRIBBLE" Spinal Cord Injury Blood Biomarker Longitudinal Evaluation · recruiting
Other University of Washington trials
Trials by the same sponsor.
- NCT07430852 — Inherited and Environmental Risks Acting on Body Weight · NA · not yet recruiting
- NCT07466498 — Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Canc · Phase 2 · not yet recruiting
- NCT06422299 — Developing and Testing an Online Intervention for Alcohol and Cannabis Misuse and Healthy Relationship Skills Among Youn · NA · not yet recruiting
- NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer · Phase 2 · not yet recruiting
- NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04056988 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Washington
- Last refreshed: 26 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04056988.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing